Northwest Biotherapeutics, Inc. is a biotechnology company, which engages in the development of personalized immune therapies for cancer. The company is headquartered in Bethesda, Maryland and currently employs 25 full-time employees. The company went IPO on 2001-12-14. The firm is focused on developing personalized immune therapies for cancer. The company has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The firm's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. The company has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.
Follow-Up Questions
Who is the CEO of Northwest Biotherapeutics Inc?
Ms. Linda Powers is the Chairperson of the Board of Northwest Biotherapeutics Inc, joining the firm since 2007.
What is the price performance of NWBO stock?
The current price of NWBO is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Northwest Biotherapeutics Inc?
Northwest Biotherapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Northwest Biotherapeutics Inc market cap?
Northwest Biotherapeutics Inc's current market cap is $NaN
